TGFß induces BIGH3 expression and human retinal pericyte apoptosis: a novel pathway of diabetic retinopathy.

PurposeOne of the earliest hallmarks of diabetic retinopathy is the loss of retinal pericytes. However, the mechanisms that promote pericyte dropout are unknown. In the present study, we propose a novel pathway in which pericyte apoptosis is mediated by macrophages, TGFß and pro-apoptotic BIGH3 (TGFß-induced Gene Human Clone 3) protein.Patients and methodsTo elucidate this pathway, we assayed human retinal pericyte (HRP) apoptosis by TUNEL assay, BIGH3 mRNA expression by qPCR, and BIGH3 protein expression by western blot analysis. HRP were treated with BIGH3 protein, TGFß1 and TGFß2 and inhibition assays were carried out by blocking with antibodies against BIGH3. The distribution of BIGH3 and CD68+ macrophages were compared in a post-mortem donor eye with 7-year history of Type II diabetes and histopathogically confirmed non-proliferative diabetic retinopathy (NPDR).ResultsTGFß induced a significant increase in BIGH3 mRNA and protein expression, and HRP apoptosis. BIGH3 treatment showed HRP undergo apoptosis in a dose-dependent manner. At 5 µg/ml, BIGH3 induced 3.5-times more apoptosis in HRP than in retinal endothelial cells. TGFß induced apoptosis was inhibited by blocking with antibodies against BIGH3. In an example of NPDR, BIGH3 accumulated within the walls of the inner retina arterioles. Macrophage infiltrates were frequently associated with these vessels and the inner nuclear layer.ConclusionTogether with our previously published results on macrophage-induced retinal endothelial cell apoptosis, the present study supports a novel inflammatory pathway mediated by macrophages and the BIGH3 protein leading to HRP apoptosis. As shown in human post-mortem globes, these observations are clinically relevant, suggesting a new mechanism underlying pericyte dropout during NPDR.

High Glucose and Glucose Deprivation Modulate Müller Cell Viability and VEGF Secretion.

PURPOSE: Diabetic retinopathy is manifested by excessive angiogenesis and high level of vascular endothelial growth factor (VEGF) in the eye. METHODS: Human (MIO-M1) and rat (rMC-1) Müller cells were treated with 0, 5.5, or 30mM glucose for 24 hours. Viable cell counts were obtained by Trypan Blue Dye Exclusion Method. ELISA was used to determine VEGF levels in cell medium. RESULTS: Compared to 24 hour treatment by 5.5mM glucose, MIO-M1 and rMC-1 in 30mM glucose increased in viable cell number by 38% and 24% respectively. In contrast, viable cells in 0mM glucose decreased by 28% and 50% respectively. Compared to 5.5mM, MIO-M1 and rMC-1 in 30mM glucose had increased levels of VEGF in cell medium (pg/ml by 24% and 20%) and also VEGF concentration in cells held in 0mM increased by 47% and 10% respectively. In both MIO-M1 and rMC-1, the amount of VEGF secreted per cell increased by about 100% when glucose was changed from 5.5 to 0mM but decreased slightly (17% in MIO-M1 and 11% in rMC-1) when glucose was increased from 5.5 to 30mM. CONCLUSIONS: Our results show that MIO-M1 and rMC-1 are highly responsive to changes in glucose concentrations. 30mM compared to 5.5mM significantly increased cell viability but induced a significant change in VEGF secretion per cell in rMC-1 only. At 0, 5.5, and 30mM glucose, MIO-M1 secreted about 5-7-fold higher level of VEGF (pg/cell) than rMC-1. The mechanism of glucose-induced changes in rMC-1 and MIO-M1 cell viability and VEGF secretion remains to be elucidated.